Menu ≡ ╳ - Home
- News
- COVID-19
- Opinion
- Business
- Regulatory
- Articles
- Intelligence
Categories
Latest Industry Intelligence
- Cancer Research
- Webinars
- Podcasts
- Archive
- Videos
Podcasts
With vaccines taking centre stage how critical is the part therapeutics have to play in the pandemic?
This DDW Sitting Down With episode features Guy Goldberg, Chief Business Officer of RedHill Biopharma. In this episode – Guy Goldberg discusses COVID-19 therapeutics and their role in the pandemic. Goldberg shares his market insight, the benefits of an orally-administered small molecule tablet for COVID treatment and how the company has maintained its success in […]
Listen nowMore Episodes
The potential of metabolomics & COVID-19 Vaccine Development
Today’s episode is titled The potential of metabolomics & COVID-19 Vaccine Development, and covers 2 articles taken from the most recent Fall issue of DDW. These articles are titled: Why metabolomics has the potential to transform diagnosis and treatment. & COVID-19 Vaccine Development: dethroning evil King Coronavirus These articles were firstly based on an interview with […]
Listen nowThe power of precision and the potential of human tissue chips
Today’s episode is titled: The power of precision and the potential of human tissue chips, and covers 2 articles taken from the most recent issue of DDW. These articles are titled: The power of precision to keep biologics effective and safe & Why we should be interested in human tissue chips These articles were written by Dr Mark […]
Listen nowThe Business Side of Drug Discovery
Today’s episode on the topic of The Business Side of Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Building the foundations for post COVID-19 R&D, Opportunity Knocks: Why compound screening libraries are worth the investment, and How to achieve data driven R&D at speed These articles were written by […]
Listen nowInnovation and Opportunity in Drug Discovery
Today’s episode on the topic of Innovation and Opportunity in Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Japanese drug development: Where is the innovation, Where are the opportunities in global drug discovery, and New for Old: The value behind drug repurposing. These articles were written by Lu […]
Listen now2030 Life Sciences and Health in the Digital Age (Part 2)
The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in 2030, in particular how the increasing adoption and sophistication of technology will affect companies and patients alike. This article is the second part of a two-part series based on […]
Listen now2030 Life Sciences and Health in the Digital Age (Part 1)
This article is the first in a two-part series based on The Pistoia Alliance report. Written in retrospect from the world as it is in 2030, it looks at how healthcare has changed in the intervening decade, covering the socio-economic and political evolutions that have happened, the subsequent effects on population health and the innovative […]
Listen nowEvolution of User Experience for life sciences
Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an evidence-based design process that centres on the behaviours and needs of users. The clear benefits of UX offered in the retail and consumer sectors have been slow to percolate to other more complex […]
Listen nowEvolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic
Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this prevalence is allowed to continue the economic and clinical burden will reach a staggering level. Non-alcoholic fatty liver disease (NAFLD) consists of a complex combination of liver maladies, ranging from benign […]
Listen nowReducing the PAINS in High Throughput Screening: Assay design as a tool for maximising efficiency
This article will describe, with examples, how understanding the likely mechanisms of false positives in advance of screening informs the design of the hit triage, thus increasing the likelihood of discovering optimisable chemical matter and avoiding costly wasting of resource. We describe the use of a bespoke ‘Robustness Set’ of nuisance compounds and how it […]
Listen nowThe COVID-19 Race: how mouse models will help researchers cross the finish line
The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission spread and relatively high mortality rates, researchers are under pressure to understand the disease’s pathogenesis, develop and test investigational therapeutics and explore […]
Listen now